Guojin Securities released a research report on April 18 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) the gradual implementation of the results of innovation and transformation; 2)

Zhitong Finance · Apr 18 09:55

Guojin Securities released a research report on April 18 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) the gradual implementation of the results of innovation and transformation; 2) the company's external BD is accelerating, and the product is about to go overseas. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

国金证券4月18日发布研报称，给予恒瑞医药（600276.SH）买入评级。评级理由主要包括：1）创新转型成果逐步兑现；2）公司对外BD加速，产品出海在即。（每日经济新闻）

Guojin Securities released a research report on April 18 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) the gradual implementation of the results of innovation and transformation; 2)

Risk Disclaimer

Statement